“N of 1” refers to a study or experiment with a single participant. In research, “n” represents the number of subjects in a study, so when n equals 1, the entire experiment revolves around one person. The term is most commonly used in medicine, where an “n-of-1 trial” is a formal clinical trial designed to find the best treatment for an individual patient rather than testing what works for a large group.
You’ll also hear the phrase used casually. When someone says “that’s just an n of 1,” they mean a single person’s experience, which isn’t enough to draw broad conclusions. Both uses stem from the same idea: a sample size of one.
How an N-of-1 Trial Works
In a traditional clinical trial, hundreds or thousands of people receive a treatment, and researchers measure the average result across the group. An n-of-1 trial flips that model. One patient cycles through different treatments (or a treatment and a placebo) in alternating periods, and the data collected over time reveals which option works best for that specific person.
A common structure is the crossover design. The patient takes treatment A for a set period, then switches to treatment B, then back to A, and so on. This is sometimes written as an “ABAB” design. Between each switch, there’s often a washout period where the patient takes nothing, allowing the previous treatment to leave their system before the next one starts. This prevents one treatment’s effects from bleeding into the next phase and muddying the results.
These trials borrow the same tools that make large studies reliable. The order of treatments can be randomized so neither the patient nor the doctor knows which phase comes first. Placebos can stand in for one of the treatments. Blinding, where the patient and the medical team don’t know which treatment is active during a given period, is considered essential for getting trustworthy results. The number of crossover periods and the length of each one depend on the condition being treated and how many data points are needed to detect a real difference.
Why One Person Can Be Enough
Large trials tell you what works on average, but averages can be misleading at the individual level. A drug that helps 60% of patients in a big study might do nothing for you specifically, and there’s no way to know from the group data alone. The goal of an n-of-1 trial is to answer a much more targeted question: does this particular treatment help this particular patient?
This makes n-of-1 trials especially valuable for chronic conditions where a patient might stay on a medication for years. Rather than committing to a drug based on population-level evidence, the patient and their doctor can test it rigorously first. The approach is also recommended for rare diseases, where recruiting enough patients for a traditional trial is difficult or impossible. A systematic review in the journal Neurology found that n-of-1 studies have been used in rare genetic neurodevelopmental disorders, often targeting neuropsychiatric symptoms like problems with cognition, behavior, and quality of life, conditions where the burden on patients and caregivers is high and standard trial options are limited.
Strengths of the Approach
The clearest advantage is personalization. Instead of relying on what helped the average patient in a study population, you get data about your own body’s response. This is particularly useful when patients respond very differently to the same treatment, which is common in pain management, mental health, and autoimmune conditions.
N-of-1 trials can also reduce unnecessary prescribing. If a crossover trial shows that a patient does just as well on placebo as on an active medication, there’s a strong case for stopping the drug and avoiding its side effects and costs. And because the trial only involves one person, it can be faster and cheaper to run than recruiting and following a large cohort.
Limitations to Keep in Mind
The most obvious limitation is generalizability. What works for one patient tells you nothing definitive about what will work for someone else. N-of-1 trials produce deeply personal evidence, not universal guidelines. Researchers can pool results from multiple n-of-1 trials to look for broader patterns, but each individual trial stands on its own.
The design also doesn’t suit every medical situation. It works best for conditions that are relatively stable over time and for treatments that act quickly and wear off quickly. A treatment with effects that build slowly over months, or a condition that naturally fluctuates in unpredictable ways, makes it hard to tell whether changes during a given period are caused by the treatment or by something else entirely. Carryover effects, where the impact of one treatment lingers into the next phase despite a washout period, are a persistent challenge. Longer treatment periods and careful statistical analysis can help, but they can’t always eliminate the problem.
There are also practical hurdles. Running a properly blinded trial for a single patient requires a pharmacy willing to prepare matched placebos, a medical team willing to manage the logistics, and a patient committed to following the protocol over weeks or months. One study in Lesch-Nyhan disease had to be stopped early because of unexpected side effects from the study drug. The researchers later noted that a run-in period, where the patient tries the drug briefly before the formal trial begins, might have caught the problem sooner.
N-of-1 in Everyday Life
Outside of formal medicine, people run informal n-of-1 experiments all the time. Trying a new supplement for a month to see if it helps your sleep, eliminating a food to check for an intolerance, or testing whether morning workouts improve your energy more than evening ones: these are all casual n-of-1 experiments. They lack the rigor of a clinical trial (no blinding, no washout periods, no randomization), but the logic is the same. You’re using yourself as the test subject and tracking the results.
Wearable technology is making these personal experiments more sophisticated. Devices that continuously track heart rate, sleep stages, activity levels, and other physiological signals generate the kind of high-frequency data that formal n-of-1 methods were designed to analyze. Researchers are actively exploring how to pair wearable data with proper n-of-1 trial designs, creating a middle ground between a casual self-experiment and a full clinical study. The continuous, real-time nature of wearable data is well suited to the repeated-measures structure of crossover designs, where you need many data points within each treatment phase to detect meaningful differences.
The Casual Use of “N of 1”
When someone dismisses a claim by saying “that’s just an n of 1,” they’re pointing out that a single person’s experience doesn’t prove a treatment works or a product is effective. This is a valid caution. One person feeling better after taking a supplement could reflect the placebo effect, natural improvement, or pure coincidence. Without a comparison condition (like a placebo phase) and repeated testing, a single anecdote can’t distinguish real effects from noise.
But the phrase is sometimes used too loosely. A properly designed n-of-1 clinical trial, with randomization, blinding, and multiple crossover periods, is not the same as a single anecdote. It’s a rigorous method for generating evidence about one person. The distinction matters: “n of 1” as a dismissal refers to uncontrolled personal experience, while “n-of-1 trial” as a research term refers to a structured experiment that happens to have one participant.